In March 2017, the US Food and Drug Administration approved ocrelizumab as the first treatment for both relapsing (RMS) and progressive forms of multiple sclerosis (MS), a genetic disease that afflicts approximately 400,000 Americans with an estimated 10,000 new cases every year. Neurologists have now looked more deeply into the impact of ocrelizumab in these patients.